PDGFRA and neoplasm: In 2018, Solomon et al. described mutations at codon p.K385 of PDGFRA, typically a dinucleotide mutation at codon 385 of the PDGFRA oncogene replacing lysine with either leucine or isoleucine (p.K385L/I), which appear to be highly characteristic for this tumor [3].